KROS logo

KEROS THERAPEUTICS INC

KROSNASDAQ
🏆 #3646 by market capEarnings Nov 3 · PostUS Equity
$84.22▼ $4.74 (−5.63%)
Simulated price
🔔
Track KROS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.6%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$222M
Small Cap
📈Revenue Growth (YoY)
-93.5%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
6.7x
Fair
Otter Score
88
Very Good
No chart data available for KROS.

Trading Snapshot

Day Range
$82.88 – $85.36
52-Week Range
$9.69 – $22.55
Volume
$2.12B
Avg Volume
$1.92B
Shares Outstanding
19.8M
Next Earnings
Dec 8, 2026

Fundamentals Snapshot

Annual Revenue
$244M
Last Q Revenue
$64M
P/E Ratio
—
P/S Ratio
6.7x
EPS (TTM)
$-3.70
Dividend Yield
—
Dilution (1yr)
−32.6%

Why Investors Own KROS

  • ✓High-growth profile — revenue up +22.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 46% gross margin and 11% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

KROS logo

KEROS THERAPEUTICS INC

KROS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$244M▲ +6775.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
99.4%▼ −0.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$71M▼ −133.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$106M▼ −165.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
27.2M▼ −32.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$271M▼ −$271M YoY
StockOtter · stockotter.space

About KEROS THERAPEUTICS INC

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Very Good
88/100

Analyst Price Target

ⓘ
Average Target
$94.12
▲ +11.8% Upside
High Target$110.68
Low Target$82.54
Based on 14 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

KEROS THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift KROS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

KEROS THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.